CureVac Trading Down 2.5 % Shares of NASDAQ:CVAC opened at $3.12 on Monday. The business has a 50 day moving average of $3.08 and a two-hundred day moving average of $3.17. The company has a ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Lilly has signed a deal with CureVac to develop up to five next-generation cancer vaccines which use messenger RNA (mRNA) technology. While previous cancer vaccines approaches have disappointed ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Bojan Pancevski is The Wall Street Journal’s chief European political correspondent, covering European and global affairs. He ...

DelveInsight's "Metastatic Cutaneous Squamous Cell Cancer Market Insights, Epidemiology, and Market Forecast- 2032" report ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

At close: April 23 at 4:00:01 PM EDT ...